Similar articles for PMID: 23220492

Year	Number of Results
1951	1
1979	1
1994	1
1998	2
2001	3
2002	1
2004	2
2005	3
2006	1
2007	1
2008	8
2009	7
2010	8
2011	8
2012	12
2013	24
2014	12
2015	20
2016	23
2017	16
2018	19
2019	18
2020	19
2021	16
2022	17
2023	4
2024	0

1

Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.

Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, Smith CP, Ward AB. Esquenazi A, et al. Toxicon. 2013 Jun 1;67:115-28. doi: 10.1016/j.toxicon.2012.11.025. Epub 2012 Dec 5. Toxicon. 2013. PMID: 23220492 Review.

2

Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.

Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Hallett M, et al. Toxicon. 2013 Jun 1;67:94-114. doi: 10.1016/j.toxicon.2012.12.004. Epub 2013 Feb 4. Toxicon. 2013. PMID: 23380701 Review.

3

Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.

Chancellor MB, Elovic E, Esquenazi A, Naumann M, Segal KR, Schiavo G, Smith CP, Ward AB. Chancellor MB, et al. Toxicon. 2013 Jun 1;67:129-40. doi: 10.1016/j.toxicon.2013.01.020. Epub 2013 Feb 13. Toxicon. 2013. PMID: 23415704 Review.

4

Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.

Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, Truong D. Naumann M, et al. Toxicon. 2013 Jun 1;67:141-52. doi: 10.1016/j.toxicon.2012.10.020. Epub 2012 Nov 23. Toxicon. 2013. PMID: 23178324 Review.

5

Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Simpson DM, et al. Neurology. 2008 May 6;70(19):1691-8. doi: 10.1212/01.wnl.0000311391.00944.c4. Neurology. 2008. PMID: 18458229

6

Clinical differences between botulinum neurotoxin type A and B.

Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Bentivoglio AR, et al. Toxicon. 2015 Dec 1;107(Pt A):77-84. doi: 10.1016/j.toxicon.2015.08.001. Epub 2015 Aug 7. Toxicon. 2015. PMID: 26260691 Review.

7

Botulinum toxin for the management of adult patients with upper motor neuron syndrome.

Esquenazi A, Mayer NH, Elia AE, Albanese A. Esquenazi A, et al. Toxicon. 2009 Oct;54(5):634-8. doi: 10.1016/j.toxicon.2009.01.022. Epub 2009 Jan 31. Toxicon. 2009. PMID: 19470335

8

Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.

Chen JJ, Dashtipour K. Chen JJ, et al. Pharmacotherapy. 2013 Mar;33(3):304-18. doi: 10.1002/phar.1196. Epub 2013 Feb 11. Pharmacotherapy. 2013. PMID: 23400888 Review.

9

Upper extremity spasticity in children with cerebral palsy: a randomized, double-blind, placebo-controlled study of the short-term outcomes of treatment with botulinum A toxin.

Koman LA, Smith BP, Williams R, Richardson R, Naughton M, Griffin L, Evans P. Koman LA, et al. J Hand Surg Am. 2013 Mar;38(3):435-46.e1. doi: 10.1016/j.jhsa.2012.12.019. J Hand Surg Am. 2013. PMID: 23428186 Clinical Trial.

10

Clinical utility of different botulinum neurotoxin preparations.

Abrams SB, Hallett M. Abrams SB, et al. Toxicon. 2013 Jun 1;67:81-6. doi: 10.1016/j.toxicon.2012.11.024. Epub 2013 Jan 30. Toxicon. 2013. PMID: 23375537 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

223 results

Results by year